Abstract Supplementary Table S1 Continuous Glucose Monitoring (CGM) has been
demonstrated to be clinically valuable, reducing risks of hypoglycemia and hyperglycemia …

Critical care, like many healthcare areas, is under a dual assault from significantly
increasing demographic and economic pressures. Intensive care unit (ICU) patients are …

The artificial pancreas (closed-loop system) addresses the unmet clinical need for improved
glucose control whilst reducing the burden of diabetes self-care in type 1 diabetes. Glucose …

Background An artificial pancreas (AP) that can be worn at home from dinner to waking up in
the morning might be safe and efficient for first routine use in patients with type 1 diabetes …

Background: Closed-loop artificial pancreas device (APD) systems are externally worn
medical devices that are being developed to enable people with type 1 diabetes to regulate …

Despite the continuous efforts devoted to AP development in the last decades, an artificial
pancreas (AP) system is not yet available on the market. One of the major issues involves …

Automated insulin delivery (AID) systems, so-called closed-loop systems or artificial
pancreas, are based upon the concept of insulin supply driven by blood glucose levels and …

Objective: High prevalence of diabetes mellitus (DM) along with the poor health outcomes
and the escalated costs of treatment and care poses the need to focus on prevention, early …

Objective: Hybrid closed-loop (HCL) artificial pancreas (AP) systems are now moving from
research settings to widespread clinical use. In this study, the inControl algorithm developed …

For patients with type 1 diabetes, closed‐loop delivery systems (CLS) combining an insulin
pump, a glucose sensor and a dosing algorithm allowing a dynamic hormonal infusion have …